Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
|Articles|February 1, 2008
Adenomyosis: More common than you think
With no clear-cut set of signs and symptoms to advertise its presence, experts suggest diagnosis may require MRI, transvaginal U/S, and/or needle biopsy. Among your treatment options: hysterectomy, GnRH agonists, and the levonorgestrel IUD.
Advertisement
Advertisement
Related to this article
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Jessica Shepherd, MD, MBA, FACOG, joins Missed & Dismissed to discuss why perimenopause is overlooked and how disparities shape who gets care.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Matthew Nudy, MD, on estrogen and the cardiovascular system
3
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
4
Mind, Body, & the Pause: Menopause, brain fog, and screening gaps, with Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG
5